Table 2.
Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-relebactam, and comparators against resistant subsets of P. aeruginosa isolates from patients with pneumonia in European hospitals in 2020
| Resistant phenotype | % Susceptible per EUCAST (no. of isolates) | ||
|---|---|---|---|
| W-EU | E-EU | All isolates | |
| Piperacillin-tazobactam-resistant (MIC > 16 mg/L) | (102) | (51) | (153) |
| Ceftazidime-avibactam | 91.2 | 70.6 | 84.3 |
| Ceftolozane-tazobactam | 78.4 | 70.0 | 75.7 |
| Imipenem-relebactam | 83.3 | 78.4 | 81.7 |
| Meropenem-vaborbactam | 69.6 | 49.0 | 62.7 |
| Meropenem-resistant (MIC > 8 mg/L) | (39) | (31) | (70) |
| Ceftazidime-avibactam | 81.6 | 54.8 | 69.9 |
| Ceftolozane-tazobactam | 59.0 | 54.8 | 57.1 |
| Imipenem-relebactam | 53.8 | 64.5 | 58.6 |
| Meropenem-vaborbactam | 7.7 | 3.2 | 5.7 |
| Imipenem-resistant (MIC > 4 mg/L) | (96) | (59) | (155) |
| Ceftazidime-avibactam | 92.6 | 78.0 | 87.0 |
| Ceftolozane-tazobactam | 84.4 | 78.0 | 81.9 |
| Imipenem-relebactam | 77.1 | 81.4 | 78.7 |
| Meropenem-vaborbactam | 63.5 | 52.5 | 59.4 |
| Ceftazidime-resistant (MIC > 8 mg/L) | (90) | (39) | (129) |
| Ceftazidime-avibactam | 87.8 | 61.5 | 79.8 |
| Ceftolozane-tazobactam | 75.6 | 61.5 | 71.3 |
| Imipenem-relebactam | 81.1 | 74.4 | 79.1 |
| Meropenem-vaborbactam | 72.2 | 46.2 | 64.3 |
| β-lactam-resistanta | (16) | (9) | (25) |
| Ceftazidime-avibactam | 81.2 | 33.3 | 64.0 |
| Ceftolozane-tazobactam | 43.8 | 55.6 | 48.0 |
| Imipenem-relebactam | 43.8 | 55.6 | 48.0 |
| Meropenem-vaborbactam | 6.2 | 0.0 | 4.0 |
aIsolates resistant to piperacillin-tazobactam (MIC > 16 mg/L), meropenem (MIC > 8 mg/L), imipenem(MIC > 4 mg/L), and ceftazidime (MIC > 8 mg/L) per EUCAST criteria [13]
Abbreviations: W-EU Western Europe, E-EU Eastern Europe